---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060505"
form_type: "8-K"
ticker: "LFST"
cik: "0001845257"
company_name: "LifeStance Health Group, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T10:49:08.403863+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeStance Q3 revenue up 21% to $262.9M, net loss widens to $61.6M, raises FY guidance midpoints

## Summary
- Revenue $262.9M (+21% YoY); clinicians up 18% to 6,418 with record organic recruiting.
- Net loss $61.6M vs $37.9M, driven by class action settlement and stock-based comp.
- Adjusted EBITDA $14.6M (5.6% of revenue) vs $15.4M (7.1%) last year.
- Raising FY 2023 guidance: revenue $1.03-1.04B, Center Margin $292-300M, Adjusted EBITDA $56-60M.
- Q4 2023 outlook: revenue $255-265M, Center Margin $73-81M, Adjusted EBITDA $17-21M.

## SEC filing metadata
- accession: 0000950170-23-060505
- form_type: 8-K
- ticker: LFST
- cik: 0001845257
- company_name: LifeStance Health Group, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845257/000095017023060505/0000950170-23-060505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845257/000095017023060505/lfst-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060505
- JSON: https://secwatch.observer/filing/0000950170-23-060505.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060505.txt

## Key facts
- Earnings Releases
  LifeStance Health Group, Inc. reported the third quarter ended September 30, 2023 results: revenue $262.9 million, net income Net loss of $61.6 million. Guidance raised.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $262.9 million
  - Net income: Net loss of $61.6 million
  - Guidance: raised
  - Result: reported results
  source text: third quarter ended September 30, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q3 2023 Highlights and FY 2023 Outlook • Total revenue of $262.9 million increased $45.3 million or 21% compared to total revenue of $217.6 million • Total clinicians of 6,418 up 18%, a sequential net increase of 286 in the third quarter • Net loss of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845257/000095017023060505/0000950170-23-060505-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.